Fuda Cancer Hospital
Fuda Cancer Hospital
Cina, Canton
| Cina | Turchia | Austria | |
| Resezione gastrica | da $18,500 | da $16,470 | da $22,000 |
| Radioterapia per il cancro colorettale | da $11,500 | da $7,000 | da $12,000 |
| Chirurgia del carcinoma gastrico | da $18,500 | da $22,320 | da $30,000 |
| Chemioterapia per carcinoma mammario | da $14,800 | da $1,200 | da $15,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Cancro gastrico stadio 2. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Cancro gastrico stadio 2 e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Cancro gastrico stadio 2.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
The standard surgical procedure for Stage 2 stomach cancer in China is radical gastrectomy combined with D2 lymphadenectomy. Surgeons perform either subtotal or total stomach removal based on tumor location. This procedure follows Chinese Society of Clinical Oncology guidelines to ensure complete tumor clearance and extensive lymph node harvest.
Bookimed Expert Insight: Chinese oncology centers demonstrate a high capacity for complex cases, with Fuda Cancer Hospital serving over 30,000 international patients. Clinical patterns show that centers in Guangzhou and Xiamen prioritize multidisciplinary teams. These teams often integrate cryosurgery or NanoKnife technologies for cases where traditional surgery requires additional local control.
Patient Consensus: Patients emphasize that final pathology reports after surgery often lead to adjustments in the treatment plan. They note it is vital to prepare for significant dietary changes and nutritional adaptation following a total gastrectomy.
Chemotherapy is common for stage 2 stomach cancer but not always mandatory after surgery. Neoadjuvant chemotherapy before surgery is standard for shrinking tumors to improve resection success. Adjuvant chemotherapy after surgery eliminates microscopic cells. The decision depends on lymph node status and tumor depth found during resection.
Bookimed Expert Insight: Patient data suggests that recovery speed often dictates the chemotherapy timeline. Fuda Cancer Hospital serves over 30,000 international patients and focuses on minimally invasive alternatives. If postoperative weight loss is severe, doctors may prioritize recovery before starting heavy drug cycles to ensure patient safety.
Patient Consensus: Patients note that stage 2 treatment plans vary. Some undergo surgery first while others start with chemo to control tumor spread. Many emphasize that post-surgical eating difficulties can make starting chemotherapy challenging.
Chinese hospitals primarily prescribe fluoropyrimidine and platinum-based doublet therapies for Stage 2 stomach cancer. The Chinese Society for Clinical Oncology guidelines recommend these after D2 gastrectomy. Standard regimens include SOX, XELOX, and FOLFOX. These protocols reduce recurrence risks and target microscopic spread.
Bookimed Expert Insight: Clinical practice in China shows a strong preference for the SOX regimen. It is more common here than in Western countries. This is because S-1 is specifically effective in East Asian populations. Patients should ensure their nutritional status is stable. Doctors at clinics like Fuda Cancer Hospital adjust doses based on body weight. This flexibility helps patients complete the full course safely.
Patient Consensus: Patients note that doctors prioritize oxaliplatin-based doublets as the modern standard. Many emphasize that dose adjustments or treatment delays are routine to manage nutrition and lab values.
International patients at top Chinese oncology centers typically see 5-year survival rates between 63% and 86% for Stage 2 stomach cancer. These rates reflect outcomes from high-volume urban institutions. Success depends on radical D2 gastrectomy and adjuvant chemotherapy. Advanced molecular profiling further improves these benchmarks.
Bookimed Expert Insight: Survival data in China is heavily influenced by surgical specialization. Facilities like Fuda Cancer Hospital have served over 30,000 patients from 100 countries. This massive volume often leads to better outcomes in complex D2 lymphadenectomies. Patients should prioritize hospitals with JCI accreditation to ensure international pathology and safety standards are met.
Patient Consensus: Patients note that survival depends on achieving clear surgical margins and adequate lymph node removal. Many emphasize that long-term recovery requires proactive management of nutrition, B12 levels, and post-operative weight loss.
International patients usually stay in China for 3 to 6 months for complete Stage 2 stomach cancer treatment. This period covers specialized surgery like radical D2 gastrectomy and multiple rounds of adjuvant chemotherapy. JCI-accredited facilities in cities like Guangzhou provide these integrated oncology protocols.
Bookimed Expert Insight: Patients can optimize their stay by choosing clinics like Fuda Cancer Hospital. This facility specializes in minimally invasive therapies that may serve as alternatives to traditional chemotherapy. Their experience with over 30,000 international patients ensures streamlined transitions between surgical recovery and local outpatient lodging.
Patient Consensus: Patients emphasize that recovery is measured in weeks rather than days. They recommend staying near the hospital after discharge to manage feeding issues or nutrition adjustments before flying home.
Chinese centers integrate Traditional Chinese Medicine (TCM) into Stage 2 stomach cancer protocols as supportive care. Major hospitals alongside Western oncology departments provide TCM to manage side effects. It never replaces the primary curative strategy of radical gastrectomy and adjuvant chemotherapy in JCI-accredited facilities.
Bookimed Expert Insight: While many search for alternative cures, Chinese oncology centers like Fuda Cancer Hospital emphasize a multidisciplinary approach. They combine Western surgery with advanced technologies like cryosurgery or NanoKnife rather than TCM alone. Our data shows these integrated centers favor TCM specifically for post-operative recovery blocks to help patients tolerate intensive chemotherapy.
Patient Consensus: Patients note that TCM is most effective for regaining their appetite and bowels after major stomach surgery. They often warn others to ensure that herbal therapies do not delay the necessary surgical staging or chemotherapy schedule.
Immunotherapy and targeted agents are not standard for Stage 2 stomach cancer in China. Most Chinese clinical protocols prioritize radical D2 surgery and cytotoxic chemotherapy. These advanced therapies are typically reserved for Stage 4 metastatic disease or specifically documented recurrence cases.
Bookimed Expert Insight: While Stage 2 standard care is surgery-focused, specialized centers like Fuda Cancer Hospital utilize over 10 types of minimally invasive therapies. These technologies, including NanoKnife and cryosurgery, provide localized alternatives to systemic drugs. This is particularly valuable for patients who cannot tolerate aggressive chemotherapy after their gastrectomy.
Patient Consensus: Patients note that D2 surgery is the expected first step. Many emphasize asking for biomarker tests early to identify long-term options if the cancer recurs.